Skip to main content
TipRanks
Go Ultimate75% OFF

Novo Nordisk (0TDD) AI Stock Analysis

11 Followers
GB:0TDD

Novo Nordisk

(LSE:0TDD)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
GLP-1 Market Position and GrowthNovo combines broad patient reach with leading GLP-1 market share and continuing obesity growth. Expanding adoption across diabetes and obesity strengthens commercial scale, supports recurring chronic-care demand, and reinforces the company’s ability to extend its position through new oral and injectable offerings.
Negative Factors
Pricing and Payer PressurePersistent price erosion can reduce the net revenue and profit contribution of Novo’s largest therapies even when prescription volumes rise. Reimbursement negotiations, PBM pressure, and employer resistance to obesity coverage may therefore constrain margin durability and limit the value of category expansion.

Novo Nordisk (0TDD) vs. iShares MSCI United Kingdom ETF (EWC)

-30%-20%-10%0%10%20%30%40%GB:0TDD-11.52%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$183.39B
Dividend Yield
4.42%
Average Volume (3M)
113.48K
Price to Earnings (P/E)
11.2
Beta (1Y)
0.86
Revenue Growth
11.16%
EPS Growth
15.62%
Country
UK
Employees
68,794
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Novo Nordisk Business Overview & Revenue Model

Company Description

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Af...

Novo Nordisk Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:1.50%|Next Earnings Date:Feb 03, 2027
Earnings Call SentimentPositive

The call was broadly positive, supported by Q3 sales and operating profit growth, improving patient volumes, strong uptake of the Wegovy and Ozempic pills, substantial clinical and pipeline progress, an accelerated international rollout, and raised 2026 guidance. However, management also highlighted near-flat full-year guidance, U.S. and international pricing pressure, loss-of-exclusivity impacts, China headwinds, payer resistance, and normalization of early Wegovy pill uptake. Highlights significantly outweighed the stated challenges.

Positive Updates

Strong Q3 Financial Performance
Adjusted sales increased 4% to DKK 79.2 billion in Q3 2026. Adjusted operating profit increased 27%, driven by GLP-1 sales growth and a favorable comparison base following approximately DKK 9 billion of company-wide transformation costs recognized in Q3 2025.

Negative Updates

2026 Growth Guidance Remains Broad and Near Flat
Despite the guidance increase, adjusted sales growth and adjusted operating profit growth for 2026 are each expected to be in the range of -2% to +2% at constant exchange rates. Management said the outlook includes sales growth in International Operations but sales decline in U.S. operations.

Company Guidance

Novo’s 2030 ambition is to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030; for 2026, adjusted sales growth is now expected to be -2% to +2% at CER, adjusted operating profit growth is now expected to be from - 2% to + 2% at constant exchange rates, and free cash flow is now expected between DKK 60 billion and DKK 70 billion. By first half of 2027, Wegovy pill is expected to be available in more than 20 markets; Frehemgo is planned to roll out globally during 2027, pending approval; denecimig is expected to launch in European countries by the turn of this year, with a broader rollout in 2027, and in the U.S. in the first half of 2027, pending regulatory decision. AMAZE 9 is expected to read out in 2028, Amylin 355 is expected to read out in the second half of 2027 in around 170 patients, ACSL5 inhibitor phase I results are anticipated in the second half of 2027, RENEW 1 and 2 phase III results are anticipated around mid-2027, and phase I/II results for both tri-agonists are anticipated in the first half of 2027.

Novo Nordisk Risk Analysis

Novo Nordisk disclosed 17 risk factors in its most recent earnings report. Novo Nordisk reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Novo Nordisk Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0TDD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SNYSNY83Outperform$116.45B25.315.84%5.00%23.68%-30.90%
LLYLLY81Outperform$1.35T46.5483.65%0.48%45.51%50.48%
AMGNAMGN75Outperform$250.07B26.6585.59%2.15%8.60%33.48%
NVSNVS72Outperform$295.59B31.0824.24%2.96%1.64%-28.72%
MRKMRK64Neutral$356.13B147.395.29%2.35%5.21%-86.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%60%GB:0TDDAMGNLLYMRKNVSSNYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0TDD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0TDDNovo Nordisk41.07-4.62-10.11%
AMGNAmgen Inc462.32127.6238.13%
LLYEli Lilly And Company1431.67407.8239.83%
MRKMerck & Company144.4650.7854.21%
NVSNovartis AG160.2034.6527.60%
SNYSanofi SA48.39-0.33-0.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.